SOTIO has completed the acquisition of Cytune Pharma for an undisclosed sum.
All products being developed by the target company will be brought into the acquirer company’s pipeline, under the acquisition.
First-in-human clinical trials for Cytune’s lead pipeline molecule SO-C101 (RLI-15) are expected to start in early 2019. SO-C101 will be a complementary addition to SOTIO’s clinical programmes in ovarian and prostate cancer based on its autologous immunotherapy platform, DCVAC.
Based in the Czech Republic, SOTIO is a biotechnology firm that is part of the PPF Group, while Cytune is a French biotechnology company engaged in the research and development of novel immunotherapeutic agents.
United Therapeutics has completed the acquisition of SteadyMed by acquiring all outstanding ordinary shares of the latter.
The acquisition was announced in April 2018 and approved by the shareholders of SteadyMed in July 2018.
Based in the US, United Therapeutics is a biotechnology company that develops and commercialises medicines for unmet medical needs, while SteadyMed, also based in the US, is a developer of therapeutic drugs.
The acquisition will enable United Therapeutics to market its pulmonary arterial hypertension drug, Trevyent® in Europe.
Canadian specialist pharmaceutical company Pediapharm has signed definitive agreements to acquire two pharmaceutical companies, Medexus and Medac Pharma.
Pediapharm has signed a stock purchase agreement with Medexus to acquire all the outstanding shares of the latter. The company has also entered an agreement with German pharmaceutical company, medac Gesellschaft, to acquire 100% shares of the latter’s US business, Medac Pharma.
Based in Canada, Medexus is a specialist pharmaceutical company, while Medac Pharma, also a specialist pharmaceutical company, is based in the US.
The acquisitions will enable Pediapharm to combine its Canadian paediatric pharmaceutical business with that of Medexus and Medac Pharma.